Lorenza Burzi

Alessandria, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

The role of dermatologist in diagnosis of acquired A hemophilia.

The role of dermatologist in diagnosis of acquired A hemophilia.

Journal: Italian journal of dermatology and venereology

Published: April 23, 2026

Impact of Disease Activity-Guided Dose Reduction on IL-17 and IL-23 Inhibitors in Psoriasis: A Real-World Assessment of Efficacy, Safety, and Economic Benefits.

Impact of Disease Activity-Guided Dose Reduction on IL-17 and IL-23 Inhibitors in Psoriasis: A Real-World Assessment of Efficacy, Safety, and Economic Benefits.

Journal: Dermatology practical & conceptual

Published: June 12, 2025

Benzyl benzoate and ivermectin are more effective than permethrin for treating scabies: A multicentre study.

Benzyl benzoate and ivermectin are more effective than permethrin for treating scabies: A multicentre study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: October 17, 2024

Rare scleromyxedema granuloma-annulare-like pattern successfully treated with intravenous immunoglobulins.

Rare scleromyxedema granuloma-annulare-like pattern successfully treated with intravenous immunoglobulins.

Journal: Italian journal of dermatology and venereology

Published: January 16, 2024

Drug survival, effectiveness, and safety of brodalumab for moderate-to-severe psoriasis up to 3 years.

Drug survival, effectiveness, and safety of brodalumab for moderate-to-severe psoriasis up to 3 years.

Journal: International journal of dermatology

Published: December 19, 2023

A case of treatment-refractory psoriasis as the first manifestation of an HIV-infection.

A case of treatment-refractory psoriasis as the first manifestation of an HIV-infection.

Journal: Italian journal of dermatology and venereology

Published: November 28, 2023

Clinical effectiveness of IL-17 and IL-23 inhibitors on difficult-to-treat psoriasis areas (scalp, genital, and palmoplantar sites): a retrospective, observational, single-center, real-life study.

Clinical effectiveness of IL-17 and IL-23 inhibitors on difficult-to-treat psoriasis areas (scalp, genital, and palmoplantar sites): a retrospective, observational, single-center, real-life study.

Journal: Expert opinion on biological therapy

Published: July 17, 2023

Drug survival, effectiveness and safety of ixekizumab for moderate-to-severe psoriasis up to 5 years.

Drug survival, effectiveness and safety of ixekizumab for moderate-to-severe psoriasis up to 5 years.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: July 14, 2023

Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study.

Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study.

Journal: Acta dermato-venereologica

Published: November 05, 2022

Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series.

Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series.

Journal: Acta dermato-venereologica

Published: August 16, 2022

Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness?

Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness?

Journal: Dermatologic therapy

Published: July 06, 2022

Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs.

Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs.

Journal: Dermatologic therapy

Published: June 15, 2022

Showing 1-12 of 22

Last Updated: 09/26/2026